Dissimilarly, chronic toxicant exposure, mutations and epigenetic modifications have all been demonstrated to activate NRF2 in a prolonged manner, resulting in tumor progression (Dodson and Zhang, 2017). This evidence concerns the gene NFE2L2 and neoplasm.